This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the COPD market through 2033.
Drug sales in the COPD drug market are expected to grow at a steady rate between 2023 and 2033, with an overall compound annual growth rate (CAGR) of 10.3% over the forecast period. In 2023, The analyst estimated the total COPD market to be valued at $11.5 billion across the 7MM, with the US accounting for 79.4% of the market. The 5EU accounted for 17.5% of the global COPD market with an estimated value of $2.0 billion, and Japan’s COPD market was estimated to be $361 million in 2023, accounting for 3.1% of the market.
Over the forecast period, the COPD market is anticipated to grow to a value of $30.8 billion in 2033, with the US anticipated to account for 78.9% of the global market and a market value of $24.3 billion. The US is forecast to grow at a CAGR of 10.3%, while the UK is anticipated to experience the fastest growth during this period with a CAGR of 15.3%, to reach a market value of $854 million by 2033.
Drug sales in the COPD drug market are expected to grow at a steady rate between 2023 and 2033, with an overall compound annual growth rate (CAGR) of 10.3% over the forecast period. In 2023, The analyst estimated the total COPD market to be valued at $11.5 billion across the 7MM, with the US accounting for 79.4% of the market. The 5EU accounted for 17.5% of the global COPD market with an estimated value of $2.0 billion, and Japan’s COPD market was estimated to be $361 million in 2023, accounting for 3.1% of the market.
Over the forecast period, the COPD market is anticipated to grow to a value of $30.8 billion in 2033, with the US anticipated to account for 78.9% of the global market and a market value of $24.3 billion. The US is forecast to grow at a CAGR of 10.3%, while the UK is anticipated to experience the fastest growth during this period with a CAGR of 15.3%, to reach a market value of $854 million by 2033.
Major drivers of growth in the COPD market during the forecast period include the following:
- The entry of anti-eosinophilic biologics, including Sanofi and Regeneron’s Dupixent, over the forecast period will boost overall COPD sales despite the low patient share that these therapies will acquire. These therapies are only suitable for COPD patients with high levels of eosinophilia, but hold a high price per unit.
- Publication and changes made to the Global Initiative for Chronic Obstructive Lung Diseases (GOLD) guidelines for therapies prescribed to GOLD E patients means an increase in inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) triple therapy use, as advised by the GOLD committee over the forecast period.
- The number of people with COPD and percentage of the drug-treated population will rise across the 7MM over the forecast period due to better awareness of COPD.
Major barriers to growth in the COPD market during the forecast period will include the following:
- The publication of GOLD guidelines and changes in the therapies given to GOLD E patients means there will be a decline in ICS/LABA being prescribed to patients over the forecast period.
- The introduction of an inhaler price cap by several pharmaceutical companies over the forecast period on various bronchodilators will mean overall sales may decrease over the forecast period, as therapies are cheaper.
- There may be low patient compliance to inhaler therapies due to the frequency of administration and dosing.
Key Highlights
- Report deliverables include a PDF report and Excel-based forecast model
- Forecasts includes the 7MM
- Forecasts covers from 2023-2033
Scope
- Overview of COPD - including epidemiology, disease etiology, management and Asthma-COPD Overlap (ACO).
- Topline COPD drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
- Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU and Japan over the 10-year forecast period.
- Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global COPD therapeutics market. Insightful review of the key industry drivers and barriers.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM COPD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM COPD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
- About the Analyst
1 Chronic Obstructive Pulmonary Disease: Executive Summary
2 Introduction
3 Disease Overview
4 Epidemiology
5 Disease Management
6 Current Treatment Options
7 Unmet Needs and Opportunity Assessment
8 R&D Strategies
9 Pipeline Assessment
10 Pipeline Valuation Analysis
11 Current and Future Players
12 Market Outlook
13 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Sanofi
- Regeneron
- GSK
- AstraZeneca
- Verona Pharma
- Chiesi Pharma
- Roche/Genentech
- Boehringer Ingelheim
- Theravance Biopharma
- Novartis
